Option chain shows key data for SBC Medical Group Holding's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for SBC Medical Group Holding.

SBC Medical Group Holding (NASDAQ:SBCWW) Stock, Option Chain

SBC Medical Group Holdings Inc is a management company that provides management services to cosmetic treatment centers mainly in Japan. It is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale). They provide management services to a total of One hundred fifty eight franchisee treatment centers under the brand name Shonan Beauty Clinic located in Japan.

SBC Medical Group Holdings Incorporated - Warrants

SBC Medical Group Holdings Inc

Raymond James analyst Buck Horne upgrades Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and announces $32 price target.

News

Upgrades

Price Target

Analyst Ratings

Raymond James Upgrades Weyerhaeuser to Outperform, Announces $32 Price Target

QuickLogic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>), a developer of embedded FPGA (eFPGA) Hard IP, ruggedized FPGAs, and endpoint AI solutions, announced today it has been awarded a $6.575 million contract. This funding will support the continued development and demonstration of Strategic Radiation Hardened (SRH) high reliability Field Programmable Gate Array (FPGA) technology. The initiative aims to meet current and future Department of Defense (DoD) strategic and space system requirements.

QUIK

QuickLogic Secures $6.6M Contract to Advance Radiation-Hardened FPGA Tech for DoD

RUM: 53% &#x7C; <a href="https://www.benzinga.com//node/42631159">Rumble shares are trading higher after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.</a>
&nbsp;
TRAW: 212% &#x7C; <a href="https://www.benzinga.com//node/42643986">Traws Pharma Advances One-Dose Bird Flu Treatment with Results</a>
&nbsp;
RAPT: 94% &#x7C; <a href="https://www.benzinga.com//node/42644215">RAPT Therapeutics To Raise $150M in Private Placement to Advance Drug Pipeline</a>

Movers

Trading Ideas

RAPT

TRAW

Market-Moving News for December 23rd

Raymond James analyst Buck Horne upgrades PotlatchDeltic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) from Market Perform to Outperform and announces $45 price target.

Raymond James Upgrades PotlatchDeltic to Outperform, Announces $45 Price Target

Alliance Global Partners analyst Aaron Grey initiates coverage on Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) with a Buy rating and announces Price Target of $2.

Initiation

WKSP

Alliance Global Partners Initiates Coverage On Worksport with Buy Rating, Announces Price Target of $2

Algorhythm Holdings, Inc. ("Algorhythm" or the "Company") (NASDAQ: RIME) – an AI technology and consumer electronics holding company, announced it will pause new capital raising activities for the next six months. In light of the Company's current cash position, combined with a comprehensive assessment of the current market environment and our business operations, our management team has decided to suspend seeking out any new financing plans for the next six months. During this period, the Company will not seek new investments including transactions like an "At-the-Market" (ATM) offering or usage of the Company's Shelf registration statement.
Additionally, the Company intends to seek the approval of its stockholders at its upcoming annual meeting of stockholders in January 2025, to implement a reverse stock split of its outstanding common stock to regain compliance with The Nasdaq Stock Market ("Nasdaq") minimum bid requirement.

Stock Split

RIME

Algorhythm Pauses Capital Raising, Plans Reverse Stock Split for Nasdaq Compliance

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) ("Psyence Biomed" or the "Company") today announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq continued listing requirements.
As previously announced, Psyence Biomed requested to be transferred from The Nasdaq Global Market to The Nasdaq Capital Market, effective November 15, 2024. As a result of this transfer, the Company regained compliance with listing rules 5550(a)(5), the $1.0 million minimum market value of publicly held shares requirement, and 5550(b)(1), the $2.5 million minimum stockholders' equity requirement.
Additionally, the Company obtained shareholder approval during its Annual General Meeting on November 12, 2024 to effect a 75-for-1 share consolidation. This share consolidation, which went into effect on November 26, 2024, was intended to address Nasdaq's listing rule 5550(a)(2), the $1 minimum bid price requirement. As the Company's shares have traded above $1 for the subsequent 18 trading days following the share consolidation, the minimum bid price requirement has been formally satisfied.

Government

Regulations

Psyence Biomed Regains Nasdaq Compliance After Share Consolidation

Piper Sandler analyst Frank Schiraldi maintains Pathward Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASH#NASDAQ">CASH</a>) with a Overweight and raises the price target from $82 to $94.

CASH

Piper Sandler Maintains Overweight on Pathward Financial, Raises Price Target to $94

Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP).

CYTK

Cytokinetics' Heart Drug Aficamten Gains EMA Validation for Review

Barclays analyst Lauren Lieberman maintains Lamb Weston Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) with a Overweight and lowers the price target from $87 to $69.

Barclays Maintains Overweight on Lamb Weston Hldgs, Lowers Price Target to $69

Lennox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), a leading provider of innovative climate control solutions, announced today its inclusion in the S&amp;P 500 Index, effective prior to the opening of trading. This milestone recognizes the company's sustained growth, innovation, and dedication to delivering advanced HVACR products that prioritize comfort and efficiency.
Widely recognized as the best single gauge of the U.S. large-cap market, the S&amp;P 500 measures the performance of 500 of the leading companies spanning all sectors of the U.S stock market. Inclusion in the index is determined by factors such as market capitalization, financial performance, and overall contribution to the economy, underscoring the success of Lennox in delivering value to shareholders and driving innovation.

Lennox Joins S&P 500, Highlighting Growth and Innovation in HVACR

Piper Sandler analyst Frank Schiraldi maintains Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) with a Overweight and raises the price target from $61 to $64.

TBBK

Piper Sandler Maintains Overweight on Bancorp, Raises Price Target to $64

Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the same period last year.

Earnings

Earnings Beats

AVXL

Anavex Life Sciences Q4 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate; Cash Of $132.2M

VYNE Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive results from the multiple ascending dose ("MAD") portion of its Phase 1a SAD/MAD trial of VYN202. The Phase 1a trial was a two-part, double-blind, placebo-controlled dose-escalation study in healthy volunteers consisting of single ascending dose ("SAD") and MAD components to evaluate the safety, tolerability, pharmacokinetics ("PK") and pharmacodynamics of VYN202.
Key Findings from the Top-line Phase 1a MAD Results for VYN202:
<ul>
<li>VYN202 demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with earlier generation, less selective bromodomain and extra-terminal domain ("BET") inhibitors, including thrombocytopenia, neutropenia or gastrointestinal toxicity findings
<ul>
<li>No serious adverse events (AEs), discontinuations due to an AE or clinically meaningful treatment emergent adverse events (TEAEs). All TEAEs were considered mild or moderate in severity.</li>
<li>No drug-related adverse events associated with laboratory results. There were no AEs of any severity grade relating to thrombocytopenia, which is a known dose-limiting toxicity associated with earlier generations of BET inhibitors. &nbsp;</li>
</ul>
</li>
<li>Favorable PK profile demonstrated for VYN202: 
<ul>
<li>Data supports once-daily dosing regimen.</li>
<li>VYN202 demonstrated dose dependent exposure that reached steady-state after 7 once-daily doses.</li>
<li>VYN202 blood levels were within key inhibitory thresholds of IC50 to IC90 against BD2 BRD4 for at least 24 hours at all doses.</li>
<li>No drug-drug interaction was observed when VYN202 was co-administered with methotrexate, a treatment commonly used in the management of chronic immuno-inflammatory conditions. &nbsp;</li>
</ul>
</li>
<li>VYN202 demonstrated robust pharmacodynamic activity on target engagement and inflammatory biomarkers in ex vivo assays: 
<ul>
<li>VYN202 induced a dose-dependent increase in the target engagement biomarker HEXIM-11 with a maximal effect observed at 0.5mg to 1.0 mg QD.</li>
<li>VYN202 inhibited the production of multiple inflammatory biomarkers related to Th17, Th1/myeloid and Th1/Tc dysregulated activity, consistent with preclinical models of VYN202.</li>
</ul>
</li>
</ul>

VYNE

VYNE Therapeutics Reports Results from Phase 1a Trial of VYN202

Barclays analyst Andrew Lazar maintains Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) with a Overweight and lowers the price target from $33 to $32.

Barclays Maintains Overweight on Conagra Brands, Lowers Price Target to $32

Piper Sandler analyst Crispin Love maintains SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) with a Neutral and raises the price target from $77 to $87.

SEIC

Piper Sandler Maintains Neutral on SEI Inv, Raises Price Target to $87

Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that the Company successfully integrated Meshy 4 into their artificial intelligence solution for game developers and publishers, Gaxos Labs.
The Meshy 4 update and integration allows artists, designers, and developers to fine-tune mesh topology, limit polycounts, and produce higher-quality 3D models faster and in a more efficient workflow. By utilizing Meshy 4's advanced generative geometry, users can seamlessly toggle between quad- or triangle-based meshes to suit the specific demands of their project. This freedom allows creators to tailor 3D assets to their exact needs—whether it's smoother surfaces for characters and animations or intricate details for complex environments. The new polycount limitation feature keeps assets from becoming resource-intensive, ensuring smoother performance and simple integration with real-time engines.

GXAI

Gaxos Enhances Game Development with Meshy 4 Integration in AI Platform

Berkshire Hathaway Chairman Warren Buffett may have had some rather sharp things to say about cryptocurrency as an asset class, but that didn't deter the veteran Wall Street investor from engaging with some of the biggest names in the industry. 
What happened: Cryptocurrency mogul and founder of Tron (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/trx/usd">TRX</a>) blockchain Justin Sun has been known for his<a href="https://www.benzinga.com/24/11/42253045/62m-duct-taped-banana-becomes-a-snack-as-crypto-mogul-justin-sun-asserts-this-conceptual-artwork-can-be-assembled-and-disassembled-anywhere"> flamboyant opulence</a>, spending millions to win bids that signal his status.
Back in 2019, Sun won the eBay charity auction to have lunch with Buffett with a record-setting $4.57 million bid. He finally <a href="https://www.benzinga.com/markets/cryptocurrency/20/02/15270316/bittorrent-ceo-justin-suns-4-5-million-dinner-with-warren-buffett">had his date</a> with the "Oracle of Omaha&#8221; on Feb. 6, 2020, bringing with him other big industry entrepreneurs like Litecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ltc/usd">LTC</a>) creator Charlie Lee.
At the time, Tron's native cryptocurrency, TRX, was priced at $0.022633. So, an investment of $1000 would have fetched you 44,183.272 units of the asset.
Cut to Dec. 2024, one TRX is valued at $0.2465. So, if you HODLed your way through the ebb and flow of the market, your stash would be worth $10,891 today, netting a massive 989% return.
See Also: <a href="https://www.benzinga.com/24/12/42640293/trump-congratulates-bitcoiners-on-new-all-time-highs-as-apex-crypto-suffers-first-weekly-loss-since-election-triumph">Trump Congratulates Bitcoin Community On New All-Time Highs Just As Top Crypto Suffers First Weekly Loss Since His Election Triumph</a>
Why It Matters: When Sun won the lunch with Buffett, he penned an open <a href="https://trondao.medium.com/an-open-letter-to-the-community-warren-buffett-charity-lunch-8c5bf25d4fe8">letter </a>saying that he would have a conversation with the Wall Street legend on cryptocurrencies and blockchain.&nbsp;
"I want to point out, though, that even one of the most successful investors of all times can sometimes miss a coming wave," Sun wrote, but admitted that even the blockchain community has a "lot to prove" about the benefits of the industry.
While we don't know what transpired between Sun and Buffett on that day, one thing is certain. The Berkshire Hathaway Chair's <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42184221/warren-buffett-once-predicted-a-bad-ending-for-crypto-since-then-the-sectors-market-cap-has-quadrupled-riding-on-the-bitcoin-dogecoin-waves">views on cryptocurrencies</a> haven't changed much.
Price Action: At the time of writing, TRX was exchanging hands at $0.2465, up 0.33 % in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. 
Image via Shutterstock
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42640482/dogecoin-flips-into-the-green-as-trump-appoints-longtime-loyalist-katie-miller-to-join-the-department-of-government-efficiency">Dogecoin Turns Green As Trump Appoints Loyalist Katie Miller To The Department Of Government Efficiency</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$LTC

$TRX

If You Invested $1000 In This Ethereum Killer When Warren Buffett Had Dinner With Justin Sun, Here's How Much You'd Have Today

Piper Sandler analyst Crispin Love maintains Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Overweight and raises the price target from $25 to $27.

Piper Sandler Maintains Overweight on Blue Owl Cap, Raises Price Target to $27

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for blarcamesine (ANAVEX&#xAE;2-73), an investigational drug for the treatment of Alzheimer's disease. The Company is looking forward to working with the EMA.
Blarcamesine is an orally once daily administered small molecule for the potential treatment of patients with Alzheimer's disease.

Anavex's Alzheimer's Drug Blarcamesine Accepted for Review by European Regulators

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

SBC Medical Group Holding

SBC Medical Group Holding (SBCWW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga